X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Following the conclusion of the call, a webcast replay will be available on the website.
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
X4 Media Contact:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
25 minutes ago
- Globe and Mail
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the 'Company') (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 39,000 shares of common stock to 5 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $10.59 per share, the Company's closing sales price on Aug. 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit
Globe and Mail
an hour ago
- Globe and Mail
Merging AI and Quantum Computing: Here's the Stock to Watch
Key Points With its cutting-edge GPUs, Nvidia is a formidable force in the AI industry. Collaborating with quantum computer developers and Japanese researchers, Nvidia is applying its AI capabilities to advance quantum computing. While Nvidia stock seems pricey, it's a no-brainer option for investors seeking both AI and quantum computing exposure. 10 stocks we like better than Nvidia › Bread is great. Meat -- or the vegetarian filling of your choice -- is great, too. But it was the Earl of Sandwich who married the two in the 1700s to create the sandwich as we know it. The race to integrate artificial intelligence (AI) and quantum computing doesn't require the ingenuity of an English nobleman. Today, tech leaders are racing to incorporate the two technologies to revolutionize computing abilities. While Nvidia (NASDAQ: NVDA) is often recognized as an AI industry stalwart, the company is also helping to advance quantum computing, making it a smart choice for those interested in gaining simultaneous exposure to the two burgeoning industries. The company for all AI seasons It's hard to overestimate Nvidia's position as an AI leader, since it has a hand in the varying niches of the AI field. Nvidia AI Foundry, for example, offers customers an end-to-end platform and service for constructing custom generative AI models, including large language models and AI chatbots. Additionally, Nvidia AI Enterprise provides a cloud-native suite of software tools, libraries, and frameworks. Nvidia's graphic processing units (GPUs) provide the backbone for its AI proficiency. The company's latest GPU architecture, Nvidia Blackwell, is in high demand from data centers, where AI computing occurs. Earlier in July, hyperscaler CoreWeave announced that it was "the first cloud provider to deliver this groundbreaking GPU architecture for AI, graphics, and high-performance computing workloads." Like CoreWeave, hyperscaler peer Nebius is rolling out availability to Blackwell architecture to customers, and the company is, unsurprisingly, extremely enthusiastic. In June, Nebius announced that the Blackwell architecture was now available to customers in Europe. With respect to the United States, Nebius is developing a data center in New Jersey that the company plans on singularly dedicating to Nvidia Blackwell-architecture GPUs. Making the quantum leap Unlike companies such as IonQ and Rigetti Computing, which are building actual quantum computers, Nvidia is taking a different -- though necessary -- tack to advancing the nascent field. For one, Nvidia is building a research center in Boston that will integrate its Nvidia GB200 Grace Blackwell superchip (providing advanced AI computing) with quantum computing hardware. The result will be accelerated quantum supercomputing that Nvidia says "will help solve quantum computing's most challenging problems, ranging from qubit noise to transforming experimental quantum processors into practical devices." A qubit is the basic unit of information in quantum computing. Providing 2,020 of its H100 GPUs interconnected by its Quantum-2 InfiniBand networking platform to Japan's National Institute of Advanced Industrial Science and Technology (AIST), Nvidia is also playing a pivotal role in facilitating progress at the ABC1-Q, the world's largest research supercomputer dedicated to quantum computing. In addition, the system is integrated with Nvidia CUDA-Q, an open-source hybrid computing platform that assists hardware and software to conduct enormous quantum computing applications. Speaking to the collaboration between Nvidia and the AIST, Tim Costa, Nvidia's senior director of computer-aided engineering, quantum and CUDA-X, was quoted as saying: Seamlessly coupling quantum hardware with AI supercomputing will accelerate realizing the promise of quantum computing for all. Nvidia's collaboration with AIST will catalyze progress in areas like quantum error correction and applications development -- crucial for building useful, accelerated quantum supercomputers. Is Nvidia a no-brainer buy today for AI and quantum computing exposure? There are several AI leaders and a handful of quantum computing pioneers, however, Nvidia is one of the very few companies developing technologies for both tech fields. This makes it an obvious consideration for those interested in a single investment that provides exposure to both corners of the tech industry. Taking a quick look at the stock's valuation, investors may conclude that shares are pricey now, trading at roughly 56 times trailing earnings. It's important to recognize, though, that Nvidia's position as a semiconductor and AI powerhouse has led to it commanding a higher valuation -- it's five-year average trailing P/E is 70. Therefore, investors shouldn't dismiss the stock as unattractively valued. And though there may be bumps in the road as these two fields mature, Nvidia is an excellent choice for investors looking to be in position to prosper from the growth of AI and quantum computing. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
Globe and Mail
an hour ago
- Globe and Mail
IES (IESC) Fiscal Q3 Revenue Up 16%
Key Points Revenue (GAAP) increased 16% to $890 million, surpassing the $833 million GAAP consensus estimate. Non-GAAP earnings per share rose 45.2% to $3.95, beating the $3.55 estimate. Strong growth in Communications and Infrastructure Solutions offset continued weakness in the Residential segment. These 10 stocks could mint the next wave of millionaires › IES (NASDAQ:IESC), a diversified specialty contractor and services provider across industrial, infrastructure, residential, and communications markets, released its fiscal third quarter results on August 1, 2025. The company reported a sharp increase in both revenue (GAAP) and net income attributable to IES compared with the third quarter of fiscal 2024, significantly outpacing Wall Street expectations. Revenue (GAAP) grew 16% to $890.2 million, topping the $833 million GAAP consensus estimate. Non-GAAP earnings per share (EPS) increased 45.2% to $3.95 compared to the prior-year period, well ahead of the expected $3.55 (non-GAAP). These results reflected strong demand in key communications and infrastructure end markets, but ongoing softness in the housing market hampered the large Residential business. Overall, the quarter marked substantial top- and bottom-line growth, underpinned by positive momentum in high-growth segments and successful execution of its acquisition strategy, despite headwinds in housing and some industrial cost pressures. Source: Analyst estimates for the quarter provided by FactSet. Business overview and strategic focus IES operates as a national provider of electrical and infrastructure services for industrial, commercial, and residential customers. Serving sectors from housing to data centers, it delivers design, construction, and maintenance across four key segments: Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The Communications segment focuses on network infrastructure, while Infrastructure Solutions specializes in custom engineered electro-mechanical solutions for industrial end markets. In recent periods, the company has sharpened its focus on segments exposed to high-growth trends, such as technology infrastructure and data centers. It has prioritized investment in capacity, targeted acquisitions to boost service offerings, and managed its balance sheet for flexibility. Major success factors include staying ahead of technology shifts, maintaining diverse revenue streams, and prudently deploying capital for growth and operational resilience. Quarterly highlights: Segment performance, strategies, and capital moves Quarterly results illustrated stark contrasts across business lines. Operating income climbed to $32.6 million, spurred by higher volumes, improved pricing, and efficiency gains, especially from investments made over the past several years. Both Communications and Infrastructure Solutions benefited from industry-wide demand for increased data processing and storage capacity. In contrast, the Residential segment continued to struggle. Revenue fell 8% to $346.1 million, and operating income (GAAP) decreased by 24%. Management directly attributed declines to a soft housing market, citing affordability constraints, insurance challenges, and economic uncertainty. Profits were also squeezed as large home builders pressured suppliers to absorb more costs, and multi-family construction backlogs in prior years continued to shrink. The segment remains the company's largest, so its underperformance remains a top risk. The Commercial & Industrial business posted 20% GAAP revenue growth, driven by rising activity in education and healthcare construction as well as data center projects. However, operating income was $12.9 million compared with $13.0 million for the third quarter of fiscal 2024. The company acknowledged that a strong contribution from a large project in the prior-year period was not repeated. This highlights how changes in project mix can influence profitability even as revenues rise. The Qypsys deal in Communications underscores continued investment in technology and infrastructure capabilities. The company ended the quarter with cash and restricted cash totaling $108.4 million and marketable securities of $66.8 million, and net long-term debt remained low at $20 million. Capital spending was $17.1 million, with $5.3 million spent this quarter and $168 million of authorization remaining. Look ahead: Guidance and key areas to watch Management did not issue formal financial guidance for either the coming quarter or full fiscal year. Instead, leaders pointed to the company's record backlog and strong end-market demand, particularly for data center infrastructure, as signs of continued growth prospects. They also stressed the long-term potential for the Residential segment, noting demographic trends and pent-up demand could drive eventual recovery once housing affordability improves. For investors tracking IES, several areas warrant close attention in future quarters. The persistence of weakness in Residential and the margin performance of Commercial & Industrial will be critical, as these offset the strength in Communications and Infrastructure Solutions. Monitoring execution on new acquisitions, progress on integrating Qypsys, and evolving backlog trends will help gauge whether growth in high-demand segments can outweigh ongoing risks tied to the housing market and volatile project margins. IES does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of July 29, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
